Xiaowei Xu

机构：China Pharmaceutical University, Drug Discovery Laboratory (Norway), State Key Laboratory of Natural Medicine · ORCID：0000-0003-1886-2728

发表论文 113 篇 · 总被引 2804 次 · h-index 29

代表论文

• PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy (2023 · Cell Metabolism · 被引 133)
• Recent Advances in PROTACs for Drug Targeted Protein Research (2022 · International Journal of Molecular Sciences · 被引 69)
• Bile acids target mitofusin 2 to differentially regulate innate immunity in physiological versus cholestatic conditions (2023 · Cell Reports · 被引 61)
• Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients (2024 · Cell Host & Microbe · 被引 34)
• A Novel Fluorescent Probe for the Detection of Hydrogen Peroxide (2023 · Biosensors · 被引 26)
• Preparation and evaluation of transdermal permeation of Huperzine A ethosomes gel in vitro (2024 · BMC Pharmacology and Toxicology · 被引 11)